Stock Research for ABIO

ABIO

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABIO Stock Chart & Research Data

The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABIO Due diligence Resources & Stock Charts

The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABIO Detailed Price Forecast - CNN Money CNN View ABIO Detailed Summary - Google Finance
Yahoo View ABIO Detailed Summary - Yahoo! Finance Zacks View ABIO Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ABIO Trends & Analysis - Trade-Ideas Barrons View ABIO Major Holders - Barrons
NASDAQ View ABIO Call Transcripts - NASDAQ Seeking View ABIO Breaking News & Analysis - Seeking Alpha
Spotlight View ABIO Annual Report - CompanySpotlight.com OTC Report View ABIO OTC Short Report - OTCShortReport.com
TradeKing View ABIO Fundamentals - TradeKing Charts View ABIO SEC Filings - Bar Chart
WSJ View Historical Prices for ABIO - The WSJ Morningstar View Performance/Total Return for ABIO - Morningstar
MarketWatch View the Analyst Estimates for ABIO - MarketWatch CNBC View the Earnings History for ABIO - CNBC
StockMarketWatch View the ABIO Earnings - StockMarketWatch MacroAxis View ABIO Buy or Sell Recommendations - MacroAxis
Bullish View the ABIO Bullish Patterns - American Bulls Short Pains View ABIO Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ABIO Stock Mentions - StockTwits PennyStocks View ABIO Stock Mentions - PennyStockTweets
Twitter View ABIO Stock Mentions - Twitter Invest Hub View ABIO Investment Forum News - Investor Hub
Yahoo View ABIO Stock Mentions - Yahoo! Message Board Seeking Alpha View ABIO Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ABIO - SECform4.com Insider Cow View Insider Transactions for ABIO - Insider Cow
CNBC View ABIO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABIO - OTC Markets
Yahoo View Insider Transactions for ABIO - Yahoo! Finance NASDAQ View Institutional Holdings for ABIO - NASDAQ


Stock Charts

FinViz View ABIO Stock Insight & Charts - FinViz.com StockCharts View ABIO Investment Charts - StockCharts.com
BarChart View ABIO Stock Overview & Charts - BarChart Trading View View ABIO User Generated Charts - Trading View




Latest Financial News for ABIO


Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details
Posted on Wednesday April 03, 2024

ARCA Biopharma Inc (NASDAQ:ABIO) and Oruka Therapeutics have entered into a definitive agreement to combine the companies in an all-stock transaction. Oruka Therapeutics is a privately held biotechnology company developing novel biologics for chronic skin diseases, including plaque psoriasis. The resulting entity will focus on advancing Oruka’s pipeline, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to o


ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
Posted on Wednesday April 03, 2024

Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations thr


ARCA biopharma Announces 2023 Financial Results
Posted on Thursday February 01, 2024

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update. In April 2022, the Board of Directors establi


We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate
Posted on Wednesday December 20, 2023

Just because a business does not make any money, does not mean that the stock will go down. For example, although...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.